Out of specification and out of trend investigations are becoming increasingly important in the pharmaceutical industry due to an increase in the number of citations given for inadequate investigations. In 2022 approximately 37 % of 483 warning letters from the FDA were issued due to failure to thoroughly review any unexplained discrepancy or the failure of the batch or any of its components to meet any of its specifications. In many cases this is down to companies being unaware of the regulatory guidance requirements while performing investigations.
Outlines how to thoroughly investigate out of specification (OOS) and out of trend (OOT) results using scientifically justified evidence to determine the root cause:
Identifying and assessing OOS results
Phase I and Phase II laboratory investigations
Manufacturing investigations
Microbiological investigations
Out of trend (OOT) investigations
Tools to help identify root causes
Reviewing OOS/OOT results
How to conclude the investigation
This course is designed for professionals in Good Manufacturing Practice (GMP) activities . It is particularly valuable for:
There are no prior qualifications or experience required to enrol in this course. It is open to all individuals interested in learning about GMP principles and practices.
Pharmaceutical consultancy
QMS / RP / QP services
based in UK and Ireland.